In This Article
- ALZN Stock Surges On AL001 Phase II Trial Milestone
- Should I Invest in ALZN Stock
Recently, Alzamend Neuro Inc. has announced its privilege of dosing the AL001 Phase II to its first patient in the clinical trial. After that, on the next morning, its stock surged 84% to $6.14, which is a big change. According to the company, AL001 is a proprietary formulation that delivers the lithium to the brain more efficiently.
Alzamend is collaborating with the Massachusetts General Hospital to study AL001’s lithium delivery performance. The aim is to compare the new product with the standard lithium carbonate, and the tests are carried out on the healthy individuals.
The company has designed the AL001 to provide better performance with the least systematic side effects and is confident that it will significantly improve patient care. The tests on other animals have been done before, providing the expected results, and this time, humans are being used in the experimentation, so the confidence of the investors, and in turn, the stock, is significantly surging.
ALZN Stock Surges On AL001 Phase II Trial Milestone
AL001 from Alzamend Neuro is the latest lithium-delivery system designed to provide the marketed lithium salt benefits but also mitigate the toxicities associated with the lithium. The new product is making a mark in the ALZN stocks, and the company is getting the reward even before the success of the experiment on humans.
Alzamend has shared the information about the working and benefits of the product; therefore, people are interested in investing more in AL001 as it will provide promising results. According to the reports, the system is designed to source the lithium to the brain, lowering its supply to the other body organs for improved safety profiles.
The currently working medicines and other products on the market perform fine, but these have side effects on the other organs as well, which cause discomfort and other issues in the body. The investors and other medicine companies are curious about its results on the human trials.
Right now, the study of the effects on humans is being conducted to see if the company is successful in creating something to help deal with the following conditions:
- Alzheimer’s disease
- Bipolar disorder
- Major depressive disorder
- Post-traumatic stress disorder
But ideally, the AL001 will help to cure more issues like this as well.
Should I Invest in ALZN Stock
While making the decision to invest anywhere, we suggest that you research the company. If you are unable to do this on your own, then you can take help from techniques like artificial intelligence. Being the experts in artificial intelligence, Weborik Hub always suggests that clients integrate the AI features into their web solutions to make them more efficient and get predictions or feedback based on real-time data.
Similarly, taking the help of the experts is the traditional and efficient way to make any decision. The experiments from the ALZN company are showing promising results; therefore, there are strong chances for the stock market scale to go up.
Alzamend CEO, Stephan Jackman says about AL001,
This advancement stands to potentially enhance the lives of over 43 million Americans suffering from Alzheimer’s, BD, MDD, and PTSD
Over the past 48 hours, the retail sentiment has jumped from “neutral” to “extremely bullish,” so we would suggest investing in the stocks and waiting for the clinical results of using the AL001 on healthy humans.
